This study monitored the incidence of venous thromboembolism in lung cancer patients to identify high-risk groups that may benefit from targeted antithrombotic prophylaxis.
May support risk-stratified VTE prophylaxis trials in lung cancer; hypothesis-generating and should not yet change practice.
Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. In a large cohort of lung cancer patients we monitored the incidence of venous thromboembolism and we identified groups of patients with the highest risk of venous thromboembolism suitable for antithrombotic prophylaxis, which could favourably affect their morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Kadlec et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: